IGA's expertise in providing innovative genomics solutions using next-generation sequencing (NGS) is now more and more employed in the medical field. Together with the Institute of Medical Genetics and the Hematological Division of Udine’s Hospital we aim to establish, within the Friuli Venezia Giulia Region, a facility of excellence for advanced molecular diagnostics and research of Acute Myeloid Leukemia (AML) by NGS approaches. The project envisages developing new competences in existing health structures operating in the regional territory and enhancing areas of excellence in research.
AML cases presenting intermediate-prognostic cytogenetic features account for about 40% of adult AMLs and display heterogeneous clinical outcomes. Over the past two decades an increasing number of molecular lesions, having prognostic and therapeutic significance, have been described, and a mounting evidence is showing that deep genomic characterization might provide an important tool to predict the progression of the disease. Identification of the genomic variants of AML by NGS is going to move medical teams closer to more precise, predictable and powerful health care that is customized for the individual patient. Our growing understanding of genetics and genomics — and how they drive health, disease and drug responses in each person — will enable doctors to provide better disease prevention, more accurate diagnoses, safer drug prescriptions and more effective treatments for the many diseases and conditions.